Renovacor, Inc.
Renovacor, Inc. (RCOR): 1 pipeline candidate · ~21 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.2 months
D/E 0.35 · 4% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for Renovacor, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$53.7M
Quarterly Burn
$7.7M
Runway
21.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| ren-001 | Preclinical |
Frequently asked questions
How many drug candidates are in Renovacor, Inc.'s pipeline?
Renovacor, Inc. (RCOR) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Renovacor, Inc.'s lead drug candidate?
Renovacor, Inc.'s most advanced tracked candidate is ren-001 (Preclinical) for BAG3-associated dilated cardiomyopathy (BAG3 DCM).
What is Renovacor, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Renovacor, Inc. has approximately 21.2 months of cash runway.
Who is the CEO of Renovacor, Inc.?
Magdalene Cook, M.D. is the chief executive officer of Renovacor, Inc. (RCOR).
Get the full picture on Renovacor, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.